| 臺大學術典藏 |
2021-01-28T01:06:14Z |
Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
|
Kun-Huei Yeh;Yang T.-S.;Hsu T.-C.;Tzu-Liang Chen W.;Chen H.-H.;Teng H.-W.;Lin B.-W.;Kuan F.-C.;Chiang F.-F.;Duann C.-W.;Li Y.-S.;Lin M.-T.;Fiala-Buskies S.;Ducreux M.;Wang J.-Y.; KUN-HUEI YEH; Yang T.-S.; Hsu T.-C.; Tzu-Liang Chen W.; Chen H.-H.; Teng H.-W.; Lin B.-W.; Kuan F.-C.; Chiang F.-F.; Duann C.-W.; Li Y.-S.; Lin M.-T.; Fiala-Buskies S.; Ducreux M.; Wang J.-Y. |
| 臺大學術典藏 |
2020-11-11T08:29:15Z |
Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan
|
Yang C.-C.; Yang C.-C.;Ro L.-S.;Tsai N.-W.;Lin C.-C.;Huang W.-N.;Tsai C.-P.;Lin T.-S.;Jen-Jen Su;Huang C.-C.;Lyu R.-K.;Chen H.-H.;Lee W.-J.;Chen P.-L.;Yang A.; Ro L.-S.; Tsai N.-W.; Lin C.-C.; Huang W.-N.; Tsai C.-P.; Lin T.-S.; JEN-JEN SU; Huang C.-C.; Lyu R.-K.; Chen H.-H.; Lee W.-J.; Chen P.-L.; Yang A. |
| 臺大學術典藏 |
2021-12-02T07:32:18Z |
Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan
|
Yang C.-C.; Ro L.-S.; Tsai N.-W.; Lin C.-C.; Huang W.-N.; Tsai C.-P.; Lin T.-S.; JEN-JEN SU; Huang C.-C.; Lyu R.-K.; Chen H.-H.; Lee W.-J.; Chen P.-L.; Yang A. |
| 國立成功大學 |
2021 |
Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan
|
Yang, C.-C.;Ro, L.-S.;Tsai, N.-W.;Lin, C.-C.;Huang, W.-N.;Tsai, C.-P.;Lin, T.-S.;Su, J.-J.;Huang, C.-C.;Lyu, R.-K.;Chen, H.-H.;Lee, W.-J.;Chen, P.-L.;Yang, A. |
| 國家衛生研究院 |
2020-08-02 |
Real-world evidence on the use of benzodiazepine receptor agonists and the risk of venous thromboembolism
|
Chen, TY;Winkelman, JW;Mao, WC;Tzeng, NS;Kuo, TBJ;Yang, CCH;Tsai, HJ;Wu, CS |
| 臺大學術典藏 |
2020-11-04T09:17:05Z |
Real-world evidence on the use of benzodiazepine receptor agonists and the risk of venous thromboembolism
|
Chen T.-Y.; Winkelman J.W.; Mao W.-C.; Tzeng N.-S.; Kuo T.B.J.; Yang C.C.H.; Tsai H.-J.; CHI-SHIN WU |
| 臺大學術典藏 |
2020-03-05T08:04:03Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Min-Shu Hsieh;Lee M.-R.;Keng L.-T.;Ko J.-C.;Shih J.-Y.; Liang S.-K.; MIN-SHU HSIEH; Lee M.-R.; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:29:35Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T02:51:01Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; MENG-RUI LEE; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:19Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
SHENG-KAI LIANG; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
